Molecularly targeted gemcitabine-loaded nanoparticulate system towards the treatment of XXXX overexpressing @entity2 .

@entity5 @entity1149 @entity2 @entity470
Molecularly targeted therapy emerged as a novel therapeutic strategy in the treatment of @entity5 . In the present study, we have developed gemcitabine (GEM)-loaded cetuximab (CET) surface modified poly(lactic) acid (PLA) nanoparticles (NP) (CET-GEM/PLA NP) to target to @entity470 ( @entity470 ) overexpressing @entity1149 (A549) cells. The resultant CET-GEM/PLA NP showed a very uniform particle size of   120nm and spherical morphology. It exhibited a pH-dependent controlled release pattern. A sustained release of drug in the physiological conditions and faster release in @entity5 pH will greatly improve the chemotherapeutic efficiency of therapeutic system. Higher or enhanced cellular uptake of CET-GEM/PLA NP in A549 @entity5 cells clearly indicates the @entity470 -mediated receptor based active targeting. Nearly, a two-fold increase in fluorescent intensity was observed for CET-GEM/PLA NP comparing to that of non-targeted NP in the @entity5 cells. @entity470 -mediated internalization of the targeted NP was further confirmed by the confocal microscopy. MTT assay clearly showed the enhanced cell killing effect of CET-conjugated NP due to the selective delivery of GEM to the @entity470 over expressing @entity5 cells. Finally, comparing to the non-targeted NP, CET-GEM/PLA NP showed greater level of cell apoptosis (early and late apoptosis   40%). Our results showed that antibody conjugation on the surface of NP could be a potential treatment strategy for @entity470 over expressing @entity5 cells. This suggests that CET-GEM/PLA NP could be potentially used for the treatment of NSCLC ( @entity2 ).
